Sep 23, 2024, 13:52
Wungki Park: Polar Maintenance: Promising Outcomes in BRCA HRD Cohorts with Pembro + Olaparib
Wungki Park, Gastrointestinal Oncologist at the Memorial Sloan Kettering Cancer Center, shared on X:
”POLAR maintenance: Cohort A HRD by BRCA2, PALB2, BRCA1 pembro + olaparib (no chemo) ORR 35%, 6M PFS rate 62% [47-82] maturing 3YOS rate 58% and rare outlier patients in Cohorts B and C. Ongoing deep science.”
Source: Wungki Park/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 26, 2024, 13:54
Sep 26, 2024, 13:50
Sep 26, 2024, 12:52
Sep 26, 2024, 12:49
Sep 26, 2024, 12:45
Sep 26, 2024, 12:37
Sep 26, 2024, 12:10
Sep 26, 2024, 12:04